Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab FTIH in mild to moderate asthma
NCT03287310Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of depemokimab in asthma (10 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious AEs (SAE), Number of Participants With Adverse Events of Special Interest (AESI) and 6 more. Started Oct 2017; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03287310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287310.